Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease

21 September 2021: Piscataway, New Jersey; Oxford and Manchester, UK; Mahwah, New Jersey.  Today, Infinity BiologiX, LLC (IBX), Cytox Ltd, and Vanguard Pharma announce the launch of the IBX Alzheimer’s Risk Test, powered by ge...

New study launched to investigate targeted treatments for Schizophrenia

Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia.  Currently, there are no treatments on...

Maxwellia strengthens its Marketing team with two new appointments

Maxwellia, the UK’s only company 100% dedicated to switching Rx to OTC medicines has created two new senior roles in its marketing team.  The team expansion follows the success of the recent landmark reclassification of the progestogen...

Rinicare’s continuous vital signs monitoring technology deployed across hospitals and Covid-19 health centres in India

Rinicare’s continuous vital signs monitoring technology platform, PRIME™, has started to be distributed across hospitals, health centres, and Covid-19 centres in Maharashtra state, India’s second most populous state with a popula...

Rinicare launches new AI-driven risk prediction solution for atrial fibrillation

The STABILITY platform uses AI technology to provide advanced clinical risk prediction, and acts as an early warning system for patient deterioration Manchester-based MedTech start-up Rinicare has launched a new application for its ground-breakin...

From our portfolio

Blueberry Therapeutics


viewview our portfolio

Our Team

Nick Wright


view complete team

Contact us

Tel: 01625 344300